Peringatan Keamanan

This reduced activity is the cause of reduced gastrointestinal toxicity, as demonstrated in several large clinical trials performed with different COXIB (see below links on NEJM and The Lancet). Some clinical trials and meta-analysis showed that treatment with COXIB lead to increased incidence of cardiovascular adverse events compared to placebo

Etoricoxib

DB01628

small molecule approved investigational

Deskripsi

Etoricoxib is a new COX-2 selective inhibitor. Current therapeutic indications are: treatment of rheumatoid arthritis, osteoarthritis, ankylosing spondylitis, chronic low back pain, acute pain and gout. Like any other COX-2 selective inhibitor, Etoricoxib selectively inhibits isoform 2 of cyclo-oxigenase enzyme (COX-2) to reduce the generation of prostaglandins (PGs) from arachidonic acid. It is approved in more than 60 countries worldwide but not in the US.

Struktur Molekul 2D

Berat 358.842
Wujud solid

Peta Jejaring Molekuler
Legenda: ObatTargetGenEnzim(Panah → menunjukkan arah efek / relasi)TransporterCarrier

Profil Farmakokinetik

Waktu Paruh (Half-Life) 22 hours
Volume Distribusi -
Klirens (Clearance) -

Absorpsi

Bioavailability is 100% following oral administration.

Metabolisme

Hepatic, primarily via CYP3A4.

Rute Eliminasi

Data eliminasi belum tersedia.

Interaksi Makanan

1 Data
  • 1. Take with or without food. The absorption is unaffected by food.

Interaksi Obat

1849 Data
Cilostazol The serum concentration of Cilostazol can be increased when it is combined with Etoricoxib.
Peginterferon alfa-2b The serum concentration of Etoricoxib can be increased when it is combined with Peginterferon alfa-2b.
Leflunomide The serum concentration of Etoricoxib can be decreased when it is combined with Leflunomide.
Teriflunomide The serum concentration of Etoricoxib can be decreased when it is combined with Teriflunomide.
Amlodipine The metabolism of Etoricoxib can be decreased when combined with Amlodipine.
Eliglustat The metabolism of Eliglustat can be decreased when combined with Etoricoxib.
Ibrutinib The metabolism of Ibrutinib can be decreased when combined with Etoricoxib.
Midodrine The risk or severity of hypertension can be increased when Midodrine is combined with Etoricoxib.
Isoetharine The risk or severity of hypertension can be increased when Isoetharine is combined with Etoricoxib.
Norepinephrine The risk or severity of hypertension can be increased when Norepinephrine is combined with Etoricoxib.
Phenylpropanolamine The risk or severity of hypertension can be increased when Phenylpropanolamine is combined with Etoricoxib.
Droperidol The risk or severity of hypertension can be increased when Droperidol is combined with Etoricoxib.
Doxapram The risk or severity of hypertension can be increased when Doxapram is combined with Etoricoxib.
Atropine The risk or severity of hypertension can be increased when Atropine is combined with Etoricoxib.
Linezolid The risk or severity of hypertension can be increased when Linezolid is combined with Etoricoxib.
Metaraminol The risk or severity of hypertension can be increased when Metaraminol is combined with Etoricoxib.
Furazolidone The risk or severity of hypertension can be increased when Furazolidone is combined with Etoricoxib.
Methoxamine The risk or severity of hypertension can be increased when Methoxamine is combined with Etoricoxib.
Propiomazine The risk or severity of hypertension can be increased when Propiomazine is combined with Etoricoxib.
Orciprenaline The risk or severity of hypertension can be increased when Orciprenaline is combined with Etoricoxib.
Phenmetrazine The risk or severity of hypertension can be increased when Phenmetrazine is combined with Etoricoxib.
Pseudoephedrine The risk or severity of hypertension can be increased when Pseudoephedrine is combined with Etoricoxib.
Ritodrine The risk or severity of hypertension can be increased when Ritodrine is combined with Etoricoxib.
Flupentixol The risk or severity of hypertension can be increased when Flupentixol is combined with Etoricoxib.
Remifentanil The risk or severity of hypertension can be increased when Remifentanil is combined with Etoricoxib.
Bitolterol The risk or severity of hypertension can be increased when Bitolterol is combined with Etoricoxib.
Oxymetazoline The risk or severity of hypertension can be increased when Oxymetazoline is combined with Etoricoxib.
Diethylpropion The risk or severity of hypertension can be increased when Diethylpropion is combined with Etoricoxib.
Naratriptan The risk or severity of hypertension can be increased when Naratriptan is combined with Etoricoxib.
Isoprenaline The risk or severity of hypertension can be increased when Isoprenaline is combined with Etoricoxib.
Arbutamine The risk or severity of hypertension can be increased when Arbutamine is combined with Etoricoxib.
Desflurane The risk or severity of hypertension can be increased when Desflurane is combined with Etoricoxib.
Isocarboxazid The risk or severity of hypertension can be increased when Isocarboxazid is combined with Etoricoxib.
Lisdexamfetamine The serum concentration of dextroamphetamine, an active metabolite of Lisdexamfetamine, can be increased when used in combination with Etoricoxib.
Fenoterol The risk or severity of hypertension can be increased when Fenoterol is combined with Etoricoxib.
Pirbuterol The risk or severity of hypertension can be increased when Pirbuterol is combined with Etoricoxib.
Ephedra sinica root The risk or severity of hypertension can be increased when Ephedra sinica root is combined with Etoricoxib.
Ephedrine The risk or severity of hypertension can be increased when Ephedrine is combined with Etoricoxib.
Mephentermine The risk or severity of hypertension can be increased when Mephentermine is combined with Etoricoxib.
Procaterol The risk or severity of hypertension can be increased when Procaterol is combined with Etoricoxib.
Clenbuterol The risk or severity of hypertension can be increased when Clenbuterol is combined with Etoricoxib.
Bambuterol The risk or severity of hypertension can be increased when Bambuterol is combined with Etoricoxib.
MMDA The risk or severity of hypertension can be increased when MMDA is combined with Etoricoxib.
2,5-Dimethoxy-4-ethylamphetamine The risk or severity of hypertension can be increased when 2,5-Dimethoxy-4-ethylamphetamine is combined with Etoricoxib.
4-Bromo-2,5-dimethoxyamphetamine The risk or severity of hypertension can be increased when 4-Bromo-2,5-dimethoxyamphetamine is combined with Etoricoxib.
Tenamfetamine The risk or severity of hypertension can be increased when Tenamfetamine is combined with Etoricoxib.
Chlorphentermine The risk or severity of hypertension can be increased when Chlorphentermine is combined with Etoricoxib.
Dextroamphetamine The risk or severity of hypertension can be increased when Dextroamphetamine is combined with Etoricoxib.
Phendimetrazine The risk or severity of hypertension can be increased when Phendimetrazine is combined with Etoricoxib.
Periciazine The risk or severity of hypertension can be increased when Periciazine is combined with Etoricoxib.
Acepromazine The risk or severity of hypertension can be increased when Acepromazine is combined with Etoricoxib.
Thioproperazine The risk or severity of hypertension can be increased when Thioproperazine is combined with Etoricoxib.
Epicaptopril The risk or severity of hypertension can be increased when Etoricoxib is combined with Epicaptopril.
Clorgiline The risk or severity of hypertension can be increased when Etoricoxib is combined with Clorgiline.
1-benzylimidazole The risk or severity of hypertension can be increased when Etoricoxib is combined with 1-benzylimidazole.
Nialamide The risk or severity of hypertension can be increased when Etoricoxib is combined with Nialamide.
Amibegron The risk or severity of hypertension can be increased when Etoricoxib is combined with Amibegron.
Naluzotan The risk or severity of hypertension can be increased when Etoricoxib is combined with Naluzotan.
Pizotifen The risk or severity of hypertension can be increased when Etoricoxib is combined with Pizotifen.
Solabegron The risk or severity of hypertension can be increased when Etoricoxib is combined with Solabegron.
Nitrous oxide The risk or severity of hypertension can be increased when Etoricoxib is combined with Nitrous oxide.
Xylometazoline The risk or severity of hypertension can be increased when Etoricoxib is combined with Xylometazoline.
Dexmethylphenidate The risk or severity of hypertension can be increased when Etoricoxib is combined with Dexmethylphenidate.
Isometheptene The risk or severity of hypertension can be increased when Etoricoxib is combined with Isometheptene.
Levonordefrin The risk or severity of hypertension can be increased when Etoricoxib is combined with Levonordefrin.
Naphazoline The risk or severity of hypertension can be increased when Etoricoxib is combined with Naphazoline.
Tetryzoline The risk or severity of hypertension can be increased when Etoricoxib is combined with Tetryzoline.
Cinitapride The risk or severity of hypertension can be increased when Etoricoxib is combined with Cinitapride.
Tyramine The risk or severity of hypertension can be increased when Etoricoxib is combined with Tyramine.
Adrafinil The risk or severity of hypertension can be increased when Etoricoxib is combined with Adrafinil.
Isoxsuprine The risk or severity of hypertension can be increased when Etoricoxib is combined with Isoxsuprine.
Ifenprodil The risk or severity of hypertension can be increased when Etoricoxib is combined with Ifenprodil.
Hexoprenaline The risk or severity of hypertension can be increased when Etoricoxib is combined with Hexoprenaline.
Etilefrine The risk or severity of hypertension can be increased when Etoricoxib is combined with Etilefrine.
Cirazoline The risk or severity of hypertension can be increased when Etoricoxib is combined with Cirazoline.
Synephrine The risk or severity of hypertension can be increased when Etoricoxib is combined with Synephrine.
Hydracarbazine The risk or severity of hypertension can be increased when Etoricoxib is combined with Hydracarbazine.
Benmoxin The risk or severity of hypertension can be increased when Etoricoxib is combined with Benmoxin.
Mebanazine The risk or severity of hypertension can be increased when Etoricoxib is combined with Mebanazine.
Octamoxin The risk or severity of hypertension can be increased when Etoricoxib is combined with Octamoxin.
Pheniprazine The risk or severity of hypertension can be increased when Etoricoxib is combined with Pheniprazine.
Phenoxypropazine The risk or severity of hypertension can be increased when Etoricoxib is combined with Phenoxypropazine.
Pivhydrazine The risk or severity of hypertension can be increased when Etoricoxib is combined with Pivhydrazine.
Safrazine The risk or severity of hypertension can be increased when Etoricoxib is combined with Safrazine.
Caroxazone The risk or severity of hypertension can be increased when Etoricoxib is combined with Caroxazone.
Iofetamine I-123 The risk or severity of hypertension can be increased when Etoricoxib is combined with Iofetamine I-123.
Racepinephrine The risk or severity of hypertension can be increased when Etoricoxib is combined with Racepinephrine.
Amitraz The risk or severity of hypertension can be increased when Etoricoxib is combined with Amitraz.
Medetomidine The risk or severity of hypertension can be increased when Etoricoxib is combined with Medetomidine.
Xylazine The risk or severity of hypertension can be increased when Etoricoxib is combined with Xylazine.
Atipamezole The risk or severity of hypertension can be increased when Etoricoxib is combined with Atipamezole.
Ractopamine The risk or severity of hypertension can be increased when Etoricoxib is combined with Ractopamine.
Romifidine The risk or severity of hypertension can be increased when Etoricoxib is combined with Romifidine.
Detomidine The risk or severity of hypertension can be increased when Etoricoxib is combined with Detomidine.
Tetrahydrocannabivarin The risk or severity of hypertension can be increased when Etoricoxib is combined with Tetrahydrocannabivarin.
PF-00610355 The risk or severity of hypertension can be increased when Etoricoxib is combined with PF-00610355.
Ritobegron The risk or severity of hypertension can be increased when Etoricoxib is combined with Ritobegron.
Abediterol The risk or severity of hypertension can be increased when Etoricoxib is combined with Abediterol.
Tulobuterol The risk or severity of hypertension can be increased when Etoricoxib is combined with Tulobuterol.
Dopexamine The risk or severity of hypertension can be increased when Etoricoxib is combined with Dopexamine.

Target Protein

Prostaglandin G/H synthase 2 PTGS2

Referensi & Sumber

Synthesis reference: Andrea Castellin, Paolo Stabile, Francesco Fontana, Ottorino De Lucchi, Andrea Caporale, Stefano Tartaggia, "PROCESS FOR PREPARING 1-(6-METHYLPYRIDIN-3-YL)-2-4-(METHYLSULFONYL)PHENYLETHANONE, AN INTERMEDIATE OF ETORICOXIB." U.S. Patent US20120232281, issued September 13, 2012.

Contoh Produk & Brand

Produk: 0 • International brands: 6
International Brands
  • Algix
  • Arcoxia
  • Coxyveen — Solmarc Lifesciences
  • Etorix
  • Nucoxia
  • Tauxib

Sekuens Gen/Protein (FASTA)

Sekuens dimuat saat dibutuhkan agar halaman tetap ringan.
© 2025 Digital Pharmacy Research - Universitas Esa Unggul